| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
BIIB
Biogen
|
Oct 29, 2026 | BUY |
Strong Buy
+6.6% avg upside
53 analysts
|
$290.00
14.42% Upside
|
+1.6% | · |
|
GILD
Gilead Sciences
|
Oct 27, 2026 | HOLD |
Strong Buy
-27.3% avg upside
66 analysts
|
$145.00
14.97% Downside
|
+6.4% | · |
|
BHVN
Biohaven Ltd.
|
Oct 23, 2026 | BUY |
Buy
+51.3% avg upside
25 analysts
|
$48.00
211.20% Upside
|
+9.4% | · |
|
NRIX
Nurix Therapeutics
|
Oct 13, 2026 | BUY |
Strong Buy
+22.5% avg upside
28 analysts
|
$36.00
34.40% Upside
|
-26.2% | · |
|
REGN
Regeneron
|
Oct 02, 2026 | HOLD |
Strong Buy
-12.1% avg upside
60 analysts
|
$761.00
17.93% Downside
|
+24.4% | · |
|
MIRM
Mirum Pharmaceuticals
|
Sep 29, 2026 | BUY |
Strong Buy
+48.1% avg upside
24 analysts
|
$130.00
53.03% Upside
|
+7.8% | · |
|
XENE
Xenon
|
Sep 18, 2026 | BUY |
Strong Buy
+53.0% avg upside
28 analysts
|
$90.00
140.49% Upside
|
+4.9% | · |
|
DYN
Dyne Therapeutics
|
Sep 09, 2026 | BUY |
Strong Buy
+116.3% avg upside
31 analysts
|
$26.00
55.79% Upside
|
-9.2% | · |
|
CLYM
Climb Bio
|
Sep 03, 2026 | BUY |
Strong Buy
+120.9% avg upside
21 analysts
|
$25.00
143.92% Upside
|
-24.5% | · |
|
ALMS
Alumis Inc.
|
Sep 01, 2026 | BUY |
Strong Buy
+361.9% avg upside
11 analysts
|
$27.00
301.21% Upside
|
-35.3% | · |
|
RGNX
RegenXBio
|
Aug 25, 2026 | BUY |
Strong Buy
+389.7% avg upside
25 analysts
|
$29.00
302.79% Upside
|
-14.5% | · |
|
PRAX
Praxis Precision Medicines
|
Aug 07, 2026 | BUY |
Strong Buy
+99.2% avg upside
25 analysts
|
$514.00
79.68% Upside
|
-7.7% | · |
|
AMGN
Amgen
|
Aug 05, 2026 | SELL |
Buy
-29.9% avg upside
57 analysts
|
$230.00
50.55% Downside
|
-14.5% | · |
|
JAZZ
Jazz Pharmaceuticals
|
Aug 04, 2026 | BUY |
Strong Buy
+16.2% avg upside
36 analysts
|
$280.00
29.62% Upside
|
-7.1% | · |
|
NBIX
Neurocrine
|
Jul 31, 2026 | BUY |
Strong Buy
+27.3% avg upside
37 analysts
|
$225.00
53.93% Upside
|
+4.6% | · |
|
VRTX
Vertex Pharmaceuticals
|
Jul 07, 2026 | SELL |
Strong Buy
-20.5% avg upside
62 analysts
|
$350.00
37.44% Downside
|
-5.0% | · |
|
ANRO
Alto Neuroscience, Inc.
|
May 18, 2026 | BUY |
Strong Buy
+43.8% avg upside
13 analysts
|
$36.00
59.20% Upside
|
+27.5% | · |
|
AXSM
Axsome Therapeutics
|
May 05, 2026 | BUY |
Strong Buy
+63.9% avg upside
30 analysts
|
$246.00
70.33% Upside
|
-34.6% | · |
|
SRPT
Sarepta Therapeutics
|
Feb 26, 2026 | HOLD |
Buy
+223.8% avg upside
50 analysts
|
$20.00
7.39% Upside
|
+2.1% | · |
|
BNTC
Benitec Biopharma
|
Dec 12, 2024 | BUY |
Strong Buy
+171.7% avg upside
15 analysts
|
$30.00
243.19% Upside
|
-3.0% | · |
|
ENTA
Enanta Pharmaceuticals
|
Nov 26, 2024 | BUY |
Buy
+206.4% avg upside
17 analysts
|
$20.00
86.75% Upside
|
+62.8% | · |
|
LXEO
Lexeo Therapeutics, Inc.
|
Nov 20, 2024 | BUY |
Strong Buy
+528.2% avg upside
11 analysts
|
$28.00
791.64% Upside
|
+45.6% | · |
|
ABUS
Arbutus Biopharma
|
Nov 06, 2024 | HOLD |
Strong Buy
+109.8% avg upside
15 analysts
|
$4.00
5.00% Downside
|
+13.3% | · |
|
OKUR
OnKure Therapeutics
|
Dec 14, 2023 | HOLD |
Buy
+743.5% avg upside
13 analysts
|
$30.00
1045.09% Upside
|
-26.4% | · |
|
VTGN
VistaGen Therapeutics
|
Nov 10, 2022 | HOLD |
Hold
+1444.8% avg upside
8 analysts
|
$7.50
4356.32% Upside
|
-34.1% | · |
|
CUE
Cue Biopharma
|
Nov 10, 2022 | BUY |
Strong Buy
-10.8% avg upside
10 analysts
|
$28.00
34.07% Upside
|
-26.0% | · |
|
IMVT
Immunovant
|
Sep 08, 2022 | HOLD |
Strong Buy
+38.4% avg upside
25 analysts
|
$6.00
79.34% Downside
|
+359.1% | · |
|
ASMB
Assembly Biosciences
|
Mar 31, 2022 | BUY |
Strong Buy
+82.7% avg upside
11 analysts
|
$15.00
25.53% Downside
|
-59.2% | · |
|
QTTB
Q32 Bio
|
Aug 12, 2021 | BUY |
Strong Buy
+523.8% avg upside
28 analysts
|
$16.00
79.59% Upside
|
-59.7% | · |
|
TIL
Instil Bio
|
Aug 12, 2021 | BUY |
Buy
+389.0% avg upside
8 analysts
|
$34.00
399.95% Upside
|
· | · |
|
CLLS
Cellectis SA
|
Aug 06, 2021 | BUY |
Strong Buy
+1837.3% avg upside
16 analysts
|
$39.00
3511.06% Upside
|
-75.8% | · |
|
NTLA
Intellia Therapeutics
|
Aug 05, 2021 | HOLD |
Buy
+187.2% avg upside
39 analysts
|
$146.00
1070.87% Upside
|
-61.7% | · |
|
VYGR
Voyager Therapeutics
|
May 10, 2021 | HOLD |
Strong Buy
+730.1% avg upside
23 analysts
|
$6.00
248.83% Upside
|
+47.2% | · |
|
TSE:BLU
BLUENERGIES
|
Jul 07, 2020 | BUY |
Strong Buy
+277.2% avg upside
1 analyst
|
$8.30
277.25% Upside
|
· | · |
|
CRIS
Curis
|
Nov 01, 2018 | BUY |
Strong Buy
+2085.2% avg upside
12 analysts
|
$3.00
399.91% Upside
|
· | · |
|
ANAB
AnaptysBio
|
Mar 27, 2018 | BUY |
Strong Buy
+48.7% avg upside
26 analysts
|
$144.00
198.29% Upside
|
-37.4% | · |
|
ONC
BeOne Medicines
|
Feb 28, 2018 | HOLD |
Strong Buy
-1.2% avg upside
29 analysts
|
$138.00
62.73% Downside
|
-4.5% | · |
|
INSM
Insmed
|
Jan 04, 2018 | BUY |
Strong Buy
+51.3% avg upside
37 analysts
|
$42.00
62.61% Downside
|
-51.2% | · |
|
BMRN
BioMarin Pharmaceutical
|
Oct 03, 2017 | BUY |
Strong Buy
+63.6% avg upside
52 analysts
|
$115.00
96.52% Upside
|
+6.9% | · |
|
INVA
Innoviva
|
Jul 26, 2017 | HOLD |
Buy
+37.9% avg upside
13 analysts
|
$13.00
38.76% Downside
|
+4.7% | · |
|
NERV
Minerva Neurosciences
|
Jan 22, 2015 | BUY |
Buy
+259.2% avg upside
8 analysts
|
$11.00
374.19% Upside
|
+3.7% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.